Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.6%

214 terminated/withdrawn out of 1289 trials

Success Rate

77.0%

-9.5% vs industry average

Late-Stage Pipeline

7%

96 trials in Phase 3/4

Results Transparency

44%

313 of 718 completed trials have results

Key Signals

193 recruiting313 with results148 terminated66 withdrawn

Enrollment Performance

Analytics

N/A
539(54.3%)
Phase 2
170(17.1%)
Phase 1
130(13.1%)
Early Phase 1
57(5.7%)
Phase 4
51(5.1%)
Phase 3
45(4.5%)
992Total
N/A(539)
Phase 2(170)
Phase 1(130)
Early Phase 1(57)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (1289)

Showing 20 of 1289 trials
NCT05424198Not ApplicableRecruiting

Trident Multi-tined Cannula for Cervical MBRFA Compared to the Conventional Cannula

Role: lead

NCT07700199Not ApplicableNot Yet Recruiting

AI-Driven Survivorship Care Plans (AI-SCP)

Role: lead

NCT07599943Not ApplicableNot Yet Recruiting

Population Health Management -Increase Lung Cancer Screening in Community Health Centers (LungSMART)

Role: lead

NCT06767566Phase 1Recruiting

Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery

Role: lead

NCT07582016Not ApplicableRecruiting

Partnership to Reduce Obesity in Community Health Center Patients (SMARTLife Utah)

Role: lead

NCT04759755Completed

Circadian Timing, Information Processing and Energy Balance Study

Role: lead

NCT07620301Not ApplicableNot Yet Recruiting

LLM Intervention for Tobacco in Underserved Populations (LIFT-UP)

Role: lead

NCT07712133Not ApplicableNot Yet Recruiting

Improving Radon Education and Awareness in Cancer Patients and Their Extended Community

Role: lead

NCT06365619Phase 2Recruiting

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

Role: lead

NCT07521046Phase 1Recruiting

Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis

Role: lead

NCT07570056Not Yet Recruiting

Use of Electrical Bioimpedance in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients (Bioimpedance)

Role: lead

NCT07849530Not ApplicableNot Yet Recruiting

Transcranial Magnetic Stimulation for Methamphetamine Use Disorder During Pregnancy

Role: lead

NCT07460440Recruiting

SPARC - Screening for Lung Cancer With Platelets Via an AI-enabled RNA-based Classifier

Role: lead

NCT06788964Phase 2Recruiting

Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)

Role: lead

NCT04537026Phase 1Completed

Sterile Amniotic Fluid Filtrate Epidural Injection.

Role: lead

NCT07840560Not ApplicableNot Yet Recruiting

Sleep Harmonization Via Bundled Team-Based Interventions in the ICU

Role: collaborator

NCT04177914Not ApplicableActive Not Recruiting

HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants

Role: lead

NCT07410689Not ApplicableRecruiting

SAFE.AI: Developing and Testing an AI-based Hybrid Chatbot for Financial Empowerment in Rural Cancer Care

Role: lead

NCT04621279Recruiting

Cool Prime Comparative Effectiveness Study for Mild HIE

Role: collaborator

NCT06866444Recruiting

Duloxetine Metabolism and Fibromyalgia

Role: lead